Statement regarding potential acquisition

RNS Number : 4736F

Alliance Pharma PLC

21 March 2022

 

For immediate release

21 March 2022

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Statement regarding potential acquisition

Alliance Pharma plc (AIM: APH), the international healthcare group, confirms that it is currently in discussions with a third party regarding a potential acquisition of two products in the US. If any acquisition did occur the total consideration for both products in aggregate would be no more than $20m.

There can be no certainty that these discussions will result in a transaction and a further announcement by the Company will be made as and when appropriate.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (withdrawal) act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under article 17 of MAR.

For further information:

Alliance Pharma plc Head of Investor Relations: Cora McCallum [e-mail]	[phone]
Buchanan Mark Court / Sophie Wills / Hannah Ratcliff [e-mail]	+ 44 (0)20 7466 5000
Numis Securities Limited Nominated Advisor: Freddie Barnfield / Duncan Monteith Corporate Broking: James Black	+ 44 (0)20 7260 1000
Investec Bank plc Corporate Finance: Daniel Adams Corporate Broking: Patrick Robb	[phone]

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END

 

 

STRUAUORUBUOUAR